European Medicines Agency decision
P/0044/2012

of 28 February 2012


Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.
European Medicines Agency decision
P/0044/2012

of 28 February 2012


The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,


Having regard to the application submitted by GlaxoSmithKline Trading Service Limited on 6 June 2011 under Article 16(1) of Regulation (EC) No 1901/2006 also requesting a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 13 January 2012, in accordance with Article 18 of Regulation (EC) No 1901/2006, and Article 21 of said Regulation and Article 13 of said Regulation,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

(1) The Paediatric Committee of the European Medicines Agency has given an opinion on the agreement of a paediatric investigation plan and on the granting of a deferral and on the granting of a waiver.

(2) It is therefore appropriate to adopt a decision agreeing a paediatric investigation plan.

(3) It is therefore appropriate to adopt a decision granting a deferral.

(4) It is therefore appropriate to adopt a decision granting a waiver.

---

Has adopted this decision:

**Article 1**

A paediatric investigation plan for N-[3-[cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-tetrahydro-3,4,6,7-tetrahydropyrido[4,3-D]pyrimidin-1(2H)-yl]phenyl]acetamide, dimethylsulfoxide solvate (GSK1120212), film-coated tablet, powder for oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby agreed.

**Article 2**

A deferral for N-[3-[cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-tetrahydro-3,4,6,7-tetrahydropyrido[4,3-D]pyrimidin-1(2H)-yl]phenyl]acetamide, dimethylsulfoxide solvate (GSK1120212), film-coated tablet, powder for oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 3**

A waiver for N-[3-[cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]-6,8-dimethyl-2,4,7-tetrahydro-3,4,6,7-tetrahydropyrido[4,3-D]pyrimidin-1(2H)-yl]phenyl]acetamide, dimethylsulfoxide solvate (GSK1120212), film-coated tablet, powder for oral solution, oral use, the details of which are set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices, is hereby granted.

**Article 4**

This decision is addressed to GlaxoSmithKline Trading Service Limited, 6900 Cork Airport Business Park, Kinsale Road, County Cork, Cork, Ireland.

Done at London, 28 February 2012

For the European Medicines Agency
Guido Rasi
Executive Director
(Signature on file)
Opinion of the Paediatric Committee on the agreement of a Paediatric Investigation Plan and a deferral and a waiver
EMA-001177-PIP01-11

Scope of the application

Active substance(s):
N-[3-[3-cyclopropyl-5-[(2-fluoro-4-iodophenyl)amino]- 6,8-dimethyl-2,4,7-trioxo-3,4,6,7-tetrahydropyrido[4,3-D]pyrimidin-1(2H)-yl]phenyl]acetamide, dimethylsulfoxide solvate (GSK1120212)

Condition(s):
Treatment of melanoma
Treatment of malignant solid tumours (excluding melanoma)

Pharmaceutical form(s):
Film-coated tablet
Powder for oral solution

Route(s) of administration:
Oral use

Name/corporate name of the PIP applicant:
GlaxoSmithKline Trading Service Limited

Basis for opinion

Pursuant to Article 16(1) of Regulation (EC) No 1901/2006 as amended, GlaxoSmithKline Trading Service Limited submitted for agreement to the European Medicines Agency on 6 June 2011 an application for a paediatric investigation plan for the above mentioned medicinal product and a deferral under Article 20 of said Regulation and a waiver under Article 13 of said Regulation.
The procedure started on 13 July 2011.

Supplementary information was provided by the applicant on 24 October 2011. The applicant proposed modifications to the paediatric investigation plan.

**Opinion**

1. The Paediatric Committee, having assessed the proposed paediatric investigation plan in accordance with Article 17 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
   - to agree the paediatric investigation plan in accordance with Article 18 of said Regulation,
   - to grant a deferral in accordance with Article 21 of said Regulation,
   - to grant a waiver for one or more subsets of the paediatric population in accordance with Article 13 of said Regulation and concluded in accordance with Article 11(1)(b) of said Regulation, on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified subset(s) of the paediatric population.

   The Icelandic and the Norwegian Paediatric Committee members agree with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the agreed paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annex(es) and appendix.

London, 13 January 2012

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)
Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan
1. Waiver

1.1. **Condition: Treatment of solid malignant tumours (excluding melanoma)**

The waiver applies to:

- Preterm and term newborn infants from birth to less than 28 days;
- for film-coated tablets, for oral use, and for powder for oral solution, for oral use;
- on the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subsets.

2. Paediatric Investigation Plan

2.1. **Condition: Treatment of melanoma**

2.1.1. **Indication(s) targeted by the PIP**

Treatment of adolescent patients with melanoma containing BRAF V600 activating mutations

2.1.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From 12 to less than 18 years of age

2.1.3. **Pharmaceutical form(s)**

Film-coated tablet.

Powder for oral solution.

2.1.4. **Studies**

<table>
<thead>
<tr>
<th>Area</th>
<th>Number of studies</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Quality</td>
<td>1</td>
<td>Study 1: Development of an age-appropriate powder for oral solution formulation of GSK1120212.</td>
</tr>
<tr>
<td>Non-clinical</td>
<td>1</td>
<td>Study 2: Juvenile rat toxicity study to evaluate toxicokinetics, clinical observations, laboratory parameters and histopathology of GSK1120212.</td>
</tr>
</tbody>
</table>
| Clinical        | 4                 | Study 3: Open-label, single agent, dose escalation trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of GSK1120212 in children from 1 month to less than 18 years of age with relapsed or refractory solid malignant tumours.  
|                 |                   | Study 4: Double-blind, randomised, controlled, parallel-group trial to evaluate the safety and efficacy of GSK1120212 in children from 1 month to less than 18 years of age with solid malignant tumours with known or expected RAS, RAF or MEK pathway activation. |
Area | Number of studies | Description
--- | --- | ---
Quality | 1 | Study 1: Same as for condition treatment of melanoma.
Non-clinical | 1 | Study 2: Same as for condition treatment of melanoma.
Clinical | 3 | Study 3: Same as for condition treatment of melanoma.
Study 4: Same as for condition treatment of melanoma.
Study 5: Same as for condition treatment of melanoma.

Study 5: Relative bioavailability study in adults.
Study 6: Measure to demonstrate that pharmacokinetics, pharmacodynamics and efficacy of GSK1120212 in adolescent patients (aged from 12 to less than 18 years of age) with BRAF V600-mutant melanoma are similar to that in adults with BRAF V600-mutant melanoma, using a modelling and simulation approach for the purpose of extrapolation of efficacy.

2.2. **Condition: Treatment of solid malignant tumours (excluding melanoma)**

2.2.1. **Indication(s) targeted by the PIP**

Treatment of paediatric patients with solid malignant tumours with known or expected RAS, RAF or MEK pathway activation.

2.2.2. **Subset(s) of the paediatric population concerned by the paediatric development**

From 1 month to less than 18 years of age.

2.2.3. **Pharmaceutical form(s)**

Film-coated tablet
Powder for oral solution

2.2.4. **Studies**

Area | Number of studies | Description
--- | --- | ---
Quality | 1 | Study 1: Same as for condition treatment of melanoma.
Non-clinical | 1 | Study 2: Same as for condition treatment of melanoma.
Clinical | 3 | Study 3: Same as for condition treatment of melanoma.
Study 4: Same as for condition treatment of melanoma.
Study 5: Same as for condition treatment of melanoma.
### 3. Follow-up, completion and deferral of PIP

<table>
<thead>
<tr>
<th>Concerns on potential long term safety and efficacy issues in relation to paediatric use:</th>
<th>Yes</th>
</tr>
</thead>
<tbody>
<tr>
<td>Date of completion of the paediatric investigation plan:</td>
<td>By October 2019</td>
</tr>
<tr>
<td>Deferral for one or more studies contained in the paediatric investigation plan:</td>
<td>Yes</td>
</tr>
</tbody>
</table>